COMBI.ST实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 21:54):

Stats
今日成交量	5 340.00
平均成交量	53 225.00
市值	74.65M
EPS	SEK-0.424 ( 2023-09-30 )
下一个收益日期	( SEK0 ) 2024-05-23
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.810
ATR14	SEK0.0240 (0.64%)

CombiGene AB (publ) 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

CombiGene AB (publ) 财务报表

Annual	2023
营收:	SEK5.54M
毛利润:	SEK-38.78M (-699.55 %)
EPS:	SEK-1.800

FY	2023
营收:	SEK5.54M
毛利润:	SEK-38.78M (-699.55 %)
EPS:	SEK-1.800

FY	2022
营收:	SEK26.70M
毛利润:	SEK-19.20M (-71.91 %)
EPS:	SEK-0.270

FY	2021
营收:	SEK84.04M
毛利润:	SEK0.00 (0.00 %)
EPS:	SEK0.200

Financial Reports:

No articles found.

CombiGene AB (publ)

CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.